ClinicalTrials.gg
CompletedNCT00490035Updated Jul 21, 2022Results posted

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

A Phase 3 interventional study of Placebo and Brivaracetam in Epilepsy, sponsored by UCB Pharma SA. Completed at 76 sites in 12 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-07-21.

Sponsored by UCB Pharma SA (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
399
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
8th of 34
399 · median 94
Started
2007
with 2 others
Phase 3
21 of 34
1 open now
Registered
9th of 34
by date
Lead sponsor
5 of 34
UCB Pharma SA

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 8th largest by enrollment, is one of 3 that started in 2007, is one of 21 in phase 3, and was the 9th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • Brivaracetam
  • Partial Onset Seizures
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects were from 16 to 70 years, both inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted
  • Subjects with well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification
  • Subjects had a history of partial onset seizures (POS) whether or not secondarily generalized (Type I seizures according to the ILAE classification)
  • Subjects had at least 2 POS whether or not secondarily generalized per month during the 3 months preceding Visit 1
  • Subjects had at least 8 POS whether or not secondarily generalized during the 8-Week Baseline Period
  • Subjects were uncontrolled while treated by 1 to 2 permitted concomitant antiepileptic drugs (AEDs). Vagal nerve stimulation was allowed and was not counted as a concomitant AED

Exclusion criteria

Exclusion Criteria:

  • History or presence of seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 3
  • History or presence of status epilepticus during the year preceding Visit 1 or during Baseline
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
399 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching Placebo tablets administered twice a day

    Other: Placebo

  • Experimental
    Brivaracetam 20 mg/day

    Brivaracetam 20 mg/day, 10 mg administered twice a day

    Drug: Brivaracetam

  • Experimental
    Brivaracetam 50 mg/day

    Brivaracetam 50 mg/day, 25 mg administered twice a day

    Drug: Brivaracetam

  • Experimental
    Brivaracetam 100 mg/day

    Brivaracetam 100 mg/day, 50 mg administered twice a day

    Drug: Brivaracetam

Interventions

  • OtherPlacebo

    Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period

  • Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period

  • Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.

  • Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.

06

What researchers measure

Primary outcomes

  1. Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period

    Partial (Type I) Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures.

    Time frame: From Baseline to 12-week Treatment Period

Secondary outcomes

  1. Responder Rate for Partial Onset Seizures (Type I) Frequency Per Week Over the 12-week Treatment Period

    Responders are those subjects with at least 50 % reduction from Baseline to Treatment Period in Partial Onset Seizure frequency per week. The Responder Rate for Partial Onset Seizures (Type I) is the proportion of subjects who have a \>= 50 % reduction in seizure frequency per week from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  2. All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period

    There are three types of Epilepsy: Partial Epilepsies (Type I), Generalized Epilepsies (Type II) and uncertain classification of Epilepsies (Type III).

    Time frame: From Baseline to 12-week Treatment Period

  3. Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week

    The percent change from Baseline was computed as: Weekly Seizure Frequency (Treatment) - Weekly Seizure Frequency (Baseline) / Weekly Seizure Frequency (Baseline) \* 100. Negative values indicate a reduction from Baseline with higher negative values showing higher reduction.

    Time frame: From Baseline to 12-week Treatment Period

  4. Categorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period

    The categories are: * \<= 25 % * - 25 % to \< 25 % * 25 % to \< 50 % * 50 % to \< 75 % * 75 % to \< 100 % * 100 %

    Time frame: From Baseline to 12-week Treatment Period

  5. Seizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period

    Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period.

    Time frame: From Baseline to 12-week Treatment Period

  6. Time to First Type I Seizure During the 12-week Treatment Period

    The time to first Type I Seizure during the 12-week Treatment Period was measured in days.

    Time frame: From Baseline to 12-week Treatment Period

  7. Time to Fifth Type I Seizure During the 12-week Treatment Period

    The time to Fifth Type I Seizure during the 12-week Treatment Period was measured in days.

    Time frame: From Baseline to 12-week Treatment Period

  8. Time to Tenth Type I Seizure During the 12-week Treatment Period

    The time to tenth Type I Seizure during the 12-week Treatment Period was measured in days.

    Time frame: From Baseline to 12-week Treatment Period

  9. Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period.

    The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.

    Time frame: From Baseline to 12-week Treatment Period

  10. Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  11. Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  12. Change From Baseline to the 12-week Treatment Period in Daily Activities/Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  13. Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score

    The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.

    Time frame: From Baseline to 12-week Treatment Period

  14. Change From Baseline to the 12-week Treatment Period in Hospital Depression Score

    The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.

    Time frame: From Baseline to 12-week Treatment Period

  15. Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit

    The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject not mentally impaired had to complete it by answering the following question: "Overall, has there been a change in your seizures since the start of the study medication?"

    Time frame: Last Visit or Early Discontinuation Visit in the 12-week Treatment Period

  16. Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit

    The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement), with the start of the study medication as reference time point. The Investigator was to complete it by answering the following question: "Assess the Overall change in the severity of patient's illness, compared to start of study medication."

    Time frame: Last Visit or Early Discontinuation Visit in the 12-week Treatment Period

  17. Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  18. Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  19. Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  20. Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  21. Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

  22. Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline to 12-week Treatment Period

07

Results

Posted Apr 13, 2016

Participant flow

This study started to enroll subjects in September 2007 and concluded in February 2009.

Participant flow — Overall Study
MilestonePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Started10099100100
Completed92938894
Not completed86126
Withdrew: Ae, non-serious non-fatal3445
Withdrew: Lost to follow-up2010
Withdrew: Withdrawal by subject2110
Withdrew: Other reason0131
Withdrew: Ae, serious fatal1000
Withdrew: Serious adverse event (sae), non-fatal0010
Withdrew: Ae of unknown type0020

Outcome measures

PrimaryPartial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period

Partial (Type I) Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Median · Seizure Frequency per Week
Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period
Seizure Frequency per WeekPlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period1.75 (0.76 to 5.12)1.34 (0.70 to 3.12)1.49 (0.69 to 2.78)1.26 (0.52 to 2.93)
Statistical analysis
  • Placebo vs Brivaracetam 50 mg/Day · ANCOVA · p = =0.261 · Percentage reduction over placebo: 6.5 · 95% CI -5.2 to 16.9
SecondaryResponder Rate for Partial Onset Seizures (Type I) Frequency Per Week Over the 12-week Treatment Period

Responders are those subjects with at least 50 % reduction from Baseline to Treatment Period in Partial Onset Seizure frequency per week. The Responder Rate for Partial Onset Seizures (Type I) is the proportion of subjects who have a \>= 50 % reduction in seizure frequency per week from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Number · Percentage of Participants
Responder Rate for Partial Onset Seizures (Type I) Frequency Per Week Over the 12-week Treatment Period
Percentage of ParticipantsPlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Non-responders80.072.772.764.0
Responders20.027.327.336.0
SecondaryAll Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period

There are three types of Epilepsy: Partial Epilepsies (Type I), Generalized Epilepsies (Type II) and uncertain classification of Epilepsies (Type III).

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Median · Times per week
All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period
Times per weekPlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period1.75 (0.76 to 5.61)1.34 (0.70 to 3.12)1.49 (0.69 to 2.78)1.26 (0.52 to 2.93)
SecondaryPercent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week

The percent change from Baseline was computed as: Weekly Seizure Frequency (Treatment) - Weekly Seizure Frequency (Baseline) / Weekly Seizure Frequency (Baseline) \* 100. Negative values indicate a reduction from Baseline with higher negative values showing higher reduction.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Median · Percent change in seizures per week
Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week
Percent change in seizures per weekPlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week-17.03 (-40.27 to 17.59)-30.03 (-55.99 to -2.11)-26.83 (-60.05 to 6.32)-32.45 (-72.51 to 0.04)
SecondaryCategorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period

The categories are: * \<= 25 % * - 25 % to \< 25 % * 25 % to \< 50 % * 50 % to \< 75 % * 75 % to \< 100 % * 100 %

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Number · Percentage of Participants
Categorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period
Percentage of ParticipantsPlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
<= 25 %19.010.115.210.0
- 25 % to < 25 %41.035.433.333.0
25 % to < 50 %20.027.324.221.0
50 % to < 75 %12.018.217.214.0
75 % to < 100 %8.07.19.118.0
100 %02.01.04.0
SecondarySeizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period

Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Number · Percentage of Participants
Seizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period
Percentage of ParticipantsPlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Seizure free02.004.0
No Seizures but non-completer001.00
Not Seizure-free100.098.099.096.0
SecondaryTime to First Type I Seizure During the 12-week Treatment Period

The time to first Type I Seizure during the 12-week Treatment Period was measured in days.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Median · Days
Time to First Type I Seizure During the 12-week Treatment Period
DaysPlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Time to First Type I Seizure During the 12-week Treatment Period4 (3 to 5)6 (3 to 8)6 (4 to 10)4 (3 to 5)
SecondaryTime to Fifth Type I Seizure During the 12-week Treatment Period

The time to Fifth Type I Seizure during the 12-week Treatment Period was measured in days.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Median · Days
Time to Fifth Type I Seizure During the 12-week Treatment Period
DaysPlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Time to Fifth Type I Seizure During the 12-week Treatment Period19 (14 to 25)25 (20 to 34)24 (20 to 32)24 (18 to 34)
SecondaryTime to Tenth Type I Seizure During the 12-week Treatment Period

The time to tenth Type I Seizure during the 12-week Treatment Period was measured in days.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Median · Days
Time to Tenth Type I Seizure During the 12-week Treatment Period
DaysPlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Time to Tenth Type I Seizure During the 12-week Treatment Period39 (24 to 50)49 (36 to 64)40 (33 to 49)46 (34 to 66)
SecondaryReduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period.

The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Number · percentage of participants
Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period.
percentage of participantsPlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period.45.947.262.541.0
SecondaryChange From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score2.29 ± 14.034.50 ± 12.713.09 ± 14.431.78 ± 13.95
SecondaryChange From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score8.25 ± 22.016.23 ± 17.975.34 ± 23.818.04 ± 26.26
SecondaryChange From Baseline to the 12-week Treatment Period in Daily Activities/Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Daily Activities/Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Change From Baseline to the 12-week Treatment Period in Daily Activities/Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score-2.09 ± 20.263.35 ± 19.723.09 ± 20.793.50 ± 22.52
SecondaryChange From Baseline to the 12-week Treatment Period in Hospital Anxiety Score

The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score-1.54 ± 3.89-0.59 ± 3.89-0.41 ± 3.820.08 ± 3.60
SecondaryChange From Baseline to the 12-week Treatment Period in Hospital Depression Score

The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Hospital Depression Score
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Change From Baseline to the 12-week Treatment Period in Hospital Depression Score-0.65 ± 3.58-0.10 ± 3.670.26 ± 3.84-0.24 ± 3.69
SecondaryPatient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit

The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject not mentally impaired had to complete it by answering the following question: "Overall, has there been a change in your seizures since the start of the study medication?"

Time frame:
Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
Reported as:
Mean · units on a scale
Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit4.93 ± 1.395.17 ± 1.275.04 ± 1.295.47 ± 1.16
SecondaryInvestigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit

The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement), with the start of the study medication as reference time point. The Investigator was to complete it by answering the following question: "Assess the Overall change in the severity of patient's illness, compared to start of study medication."

Time frame:
Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
Reported as:
Mean · units on a scale
Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit4.78 ± 1.204.99 ± 1.154.99 ± 1.105.34 ± 1.12
SecondaryChange From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score3.49 ± 19.223.53 ± 17.041.95 ± 20.741.99 ± 20.42
SecondaryChange From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score3.80 ± 18.713.75 ± 15.943.13 ± 19.35-2.45 ± 18.55
SecondaryChange From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score1.80 ± 19.165.36 ± 20.691.02 ± 19.950.69 ± 16.66
SecondaryChange From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score0.92 ± 28.933.64 ± 29.24-0.85 ± 24.363.00 ± 28.22
SecondaryChange From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score5.11 ± 18.484.52 ± 16.734.55 ± 18.932.24 ± 18.45
SecondaryChange From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score6.6 ± 16.36.9 ± 20.19.7 ± 19.84.9 ± 18.1

Adverse events

Collected over Adverse Events (AEs) were collected up to 23 weeks from Visit 1 (Week -8) to the Safety Visit (Week 15).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—6/100 (6%)22/100 (22%)
Brivaracetam 20 mg/Day—2/99 (2%)31/99 (31.3%)
Brivaracetam 50 mg/Day—4/99 (4%)35/99 (35.4%)
Brivaracetam 100 mg/Day—2/100 (2%)37/100 (37%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
ConvulsionNervous system disorders3/1000/991/990/100
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/1001/990/990/100
AmnesiaPsychiatric disorders0/1000/991/990/100
Gastritis erosiveGastrointestinal disorders0/1000/991/990/100
Grand mal convulsionNervous system disorders0/1000/991/990/100
Jaw fractureInjury, poisoning and procedural complications0/1001/990/990/100
Psychotic DisorderPsychiatric disorders0/1000/991/990/100
Vaginal hemorrhageReproductive system and breast disorders0/1001/990/990/100
Angina pectorisCardiac disorders1/1000/990/990/100
Humerus fractureInjury, poisoning and procedural complications0/1000/990/991/100
Most frequent other events
Most frequent other events
EventPlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/Day
HeadacheNervous system disorders10/10014/9918/999/100
NasopharyngitisInfections and infestations1/1008/991/992/100
SomnolenceNervous system disorders6/1008/996/998/100
FatigueGeneral disorders2/1003/994/998/100
VertigoEar and labyrinth disorders3/1001/992/998/100
DizzinessNervous system disorders5/1005/997/995/100
NauseaGastrointestinal disorders4/1000/991/996/100
ConvulsionNervous system disorders1/1005/991/992/100
IrritabilityPsychiatric disorders0/1000/995/991/100

Baseline characteristics

Baseline Characteristics refer to the Randomized Set.

Age, Continuous
Age, Continuous(years)PlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/DayTotal Title
Mean36.4 ± 13.035.7 ± 12.539.0 ± 13.538.0 ± 13.137.24 ± 13.05
Age, Customized
Age, Customized(participants)PlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/DayTotal Title
<18 years22015
Between 18 and 65 years96949796383
>=65 years233311
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/DayTotal Title
Female46384542171
Male54615558228
Region of Enrollment
Region of Enrollment(Participants)PlaceboBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayBrivaracetam 100 mg/DayTotal Title
Hungary423312
Poland26282727108
India2322232391
Belgium30306
Finland331411
France1717111560
Germany81014941
Italy483520
Netherlands30137
Spain846422
Switzerland136515
United Kingdom02226
08

Study locations

76 sites
  • 13
    Gent, Belgium
  • 19
    La Louviere, Belgium
  • 12
    Liege, Belgium
  • 10
    Saint-Vith, Belgium
  • 44
    Kuopio, Finland
  • 41
    Oulu, Finland
  • 42
    Seinajoki, Finland
  • 43
    Tampere, Finland
  • 60
    Angers Cedex 9, France
  • 56
    Bethune, France
  • 62
    Bron, France
  • 57
    Dijon, France
  • 53
    Lille, France
  • 52
    Montpellier Cedex, France
  • 64
    Nancy, France
  • 54
    Paris, France
  • 51
    Rennes, France
  • 61
    Roanne, France
  • 55
    Strasbourg, France
  • 76
    Bad Berka, Germany
  • 73
    Berlin, Germany
  • 79
    Bernau, Germany
  • 78
    Bielefeld, Germany
  • 74
    Freiburg, Germany
  • 75
    Kehl-Kork, Germany
  • 77
    Mainz, Germany
  • 70
    Munchen, Germany
  • 72
    Radeberg, Germany
  • 71
    Ulm, Germany
  • 94
    Budapest, Hungary
  • 90
    Debrecen, Hungary
  • 92
    Pecs, Hungary
  • 256
    Bangalore, India
  • 257
    Bangalore, India
  • 253
    Hyderabad, India
  • 258
    Jaipur, India
  • 255
    Kolkata, India
  • 250
    Lucknow, India
  • 259
    Mumbai, India
  • 251
    Pune Maharashtra, India
  • 270
    Pune, India
  • 104
    Bologna, Italy
  • 105
    Foggia, Italy
  • 101
    Perugia, Italy
  • 103
    Roma, Italy
  • 107
    Roma, Italy
  • 124
    Breda, Netherlands
  • 125
    Den Haag, Netherlands
  • 122
    Zwolle, Netherlands
  • 142
    Bialystok, Poland
  • 143
    Gdansk, Poland
  • 153
    Grodzisk Mazowiecki, Poland
  • 147
    Katowice, Poland
  • 151
    Katowice, Poland
  • 141
    Kielce, Poland
  • 150
    Krakow, Poland
  • 148
    Lodz, Poland
  • 144
    Lublin, Poland
  • 152
    Poznan, Poland
  • 146
    Szczecin, Poland
  • 145
    Warsaw, Poland
  • 140
    Warszawa, Poland
  • 149
    Warszawa, Poland
  • 187
    Alcorcon, Spain
  • 181
    Barcelona, Spain
  • 182
    Madrid, Spain
  • 184
    San Sebastian, Spain
  • 183
    Vigo, Spain
  • 185
    Zaragoza, Spain
  • 201
    Biel, Switzerland
  • 205
    Geneve, Switzerland
  • 203
    St Gallen, Switzerland
  • 202
    Tschugg, Switzerland
  • 204
    Zürich, Switzerland
  • 223
    Liverpool, United Kingdom
  • 224
    Middlesborough, United Kingdom
09

References and documents

Publications

  • Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014 Jan;55(1):47-56. doi: 10.1111/epi.12432. Epub 2013 Oct 28. PubMed 24256083 ↗
  • Toledo M, Whitesides J, Schiemann J, Johnson ME, Eckhardt K, McDonough B, Borghs S, Kwan P. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016 Jul;57(7):1139-51. doi: 10.1111/epi.13416. Epub 2016 Jun 6. PubMed 27265725 ↗
  • Ben-Menachem E, Mameniskiene R, Quarato PP, Klein P, Gamage J, Schiemann J, Johnson ME, Whitesides J, McDonough B, Eckhardt K. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016 Jul 19;87(3):314-23. doi: 10.1212/WNL.0000000000002864. Epub 2016 Jun 22. PubMed 27335114 ↗
  • Brodie MJ, Whitesides J, Schiemann J, D'Souza J, Johnson ME. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies. Epilepsy Res. 2016 Nov;127:114-118. doi: 10.1016/j.eplepsyres.2016.08.018. Epub 2016 Aug 18. PubMed 27589414 ↗
  • Mukuria C, Young T, Keetharuth A, Borghs S, Brazier J. Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam. Qual Life Res. 2017 Mar;26(3):749-759. doi: 10.1007/s11136-016-1483-3. Epub 2016 Dec 21. PubMed 28004320 ↗
  • Moseley BD, Sperling MR, Asadi-Pooya AA, Diaz A, Elmouft S, Schiemann J, Whitesides J. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies. Epilepsy Res. 2016 Nov;127:179-185. doi: 10.1016/j.eplepsyres.2016.09.003. Epub 2016 Sep 3. PubMed 27608437 ↗
  • Brandt C, Borghs S, Elmoufti S, Mueller K, Townsend R, de la Loge C. Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis. Epilepsy Behav. 2017 Apr;69:80-85. doi: 10.1016/j.yebeh.2016.11.031. Epub 2017 Feb 23. PubMed 28236727 ↗
  • Klein P, Johnson ME, Schiemann J, Whitesides J. Time to onset of sustained >/=50% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment. Epilepsia. 2017 Feb;58(2):e21-e25. doi: 10.1111/epi.13631. Epub 2016 Dec 18. PubMed 27988967 ↗
  • Asadi-Pooya AA, Sperling MR, Chung S, Klein P, Diaz A, Elmoufti S, Schiemann J, Whitesides J. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study. Epilepsy Res. 2017 Mar;131:70-75. doi: 10.1016/j.eplepsyres.2017.02.007. Epub 2017 Feb 27. Erratum In: Epilepsy Res. 2017 Nov;137:165-166. doi: 10.1016/j.eplepsyres.2017.04.019. PubMed 28279891 ↗
  • Benbadis S, Klein P, Schiemann J, Diaz A, Elmoufti S, Whitesides J. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis. Epilepsy Behav. 2018 Mar;80:129-134. doi: 10.1016/j.yebeh.2017.12.024. Epub 2018 Feb 3. PubMed 29414542 ↗
  • Brodie MJ, Fakhoury T, McDonough B, Colson AO, Stockis A, Elmoufti S, Whitesides J. Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program. Epilepsy Res. 2018 Sep;145:55-62. doi: 10.1016/j.eplepsyres.2018.06.002. Epub 2018 Jun 4. PubMed 29908435 ↗
  • Klein P, Laloyaux C, Elmoufti S, Gasalla T, Martin MS. Time course of 75%-100% efficacy response of adjunctive brivaracetam. Acta Neurol Scand. 2020 Aug;142(2):175-180. doi: 10.1111/ane.13287. Epub 2020 Jun 9. PubMed 32432339 ↗
  • Moseley BD, Dimova S, Elmoufti S, Laloyaux C, Asadi-Pooya AA. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis. Epilepsy Res. 2021 Oct;176:106694. doi: 10.1016/j.eplepsyres.2021.106694. Epub 2021 Jun 24. PubMed 34218211 ↗
  • Ryvlin P, Dimova S, Elmoufti S, Floricel F, Laloyaux C, Nondonfaz X, Biton V. Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials. Epilepsia. 2022 Aug;63(8):2024-2036. doi: 10.1111/epi.17304. Epub 2022 Jun 10. PubMed 35582748 ↗
  • Bresnahan R, Panebianco M, Marson AG. Brivaracetam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev. 2022 Mar 14;3(3):CD011501. doi: 10.1002/14651858.CD011501.pub3. PubMed 35285519 ↗
  • Lee SK, Heo K, Kim SE, Lee SA, Elmoufti S, Laloyaux C, Hur B. Effect of Number of Previous Antiseizure Medications on Efficacy and Tolerability of Adjunctive Brivaracetam for Uncontrolled Focal Seizures: Post Hoc Analysis. Adv Ther. 2021 Jul;38(7):4082-4099. doi: 10.1007/s12325-021-01816-5. Epub 2021 Jun 21. PubMed 34155568 ↗
  • Ben-Menachem E, Baulac M, Hong SB, Cleveland JM, Reichel C, Schulz AL, Wagener G, Brandt C. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial. Epilepsy Res. 2021 Feb;170:106526. doi: 10.1016/j.eplepsyres.2020.106526. Epub 2020 Dec 4. PubMed 33461041 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 7 years 2 months after primary completion. A results delay was requested in Feb 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2007
First posted
Jun 22, 2007
Start
Sep 2007
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results delay requested
Feb 24, 2010
Results first posted
Apr 13, 2016
Last update
Jul 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00490035
Lead sponsor
UCB Pharma SA
Responsible party
Sponsor
First posted
Jun 22, 2007
Start date
Sep 2007
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Apr 13, 2016
Last update
Jul 21, 2022

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion